Related Experiment Videos
Erythropoietin use in a Jehovah's Witness patient
The Annals of Pharmacotherapy
|April 9, 2002
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Seroconversion following Heplisav-B, hepatitis B vaccine (recombinant), adjuvanted, in patients with end-stage renal disease at an urban safety net hospital.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2023
Management of an i.v. fluid shortage through use of electronic medical record alerts.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2020
Management of hyperkalemia in hospitalized patients.
The American journal of the medical sciences·2012
Once-weekly vancomycin for patients receiving high-flux hemodialysis.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2008
Role of acetylcysteine in the prevention of contrast-media-induced nephrotoxicity.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2003
Alteplase versus urokinase in restoring blood flow in hemodialysis-catheter thrombosis.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2002
Pharmacologic Strategies for Anemia in Patient Blood Management: A Systematic Review and Practical Clinical Synthesis.
The Annals of pharmacotherapy·2026
Efficacy and Safety of Levetiracetam Versus Sodium Valproate in Pediatric Epilepsy: A Systematic Review and Meta-analysis.
The Annals of pharmacotherapy·2026
Doravirine/Islatravir: A 2-Drug Regimen for the Treatment of HIV-1 Infection.
The Annals of pharmacotherapy·2026
Obecabtagene Autoleucel in Relapsed/Refractory B-ALL: A Critical Review of Clinical Efficacy and Safety.
The Annals of pharmacotherapy·2026
Depemokimab-ulaa: A Long-Acting Interleukin-5 Inhibitor.
The Annals of pharmacotherapy·2026